- Home
- GEVO vs EBS Comparison
GEVO vs EBS Comparison
Compare GEVO & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEVO
- EBS
- Stock Information
- Founded
- GEVO 2005
- EBS 1998
- Country
- GEVO United States
- EBS United States
- Employees
- GEVO N/A
- EBS N/A
- Industry
- GEVO Major Chemicals
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- GEVO Industrials
- EBS Health Care
- Exchange
- GEVO Nasdaq
- EBS Nasdaq
- Market Cap
- GEVO 498.2M
- EBS 529.9M
- IPO Year
- GEVO 2011
- EBS 2006
- Fundamental
- Price
- GEVO $1.91
- EBS $10.05
- Analyst Decision
- GEVO Buy
- EBS Strong Buy
- Analyst Count
- GEVO 2
- EBS 2
- Target Price
- GEVO $8.13
- EBS $13.50
- AVG Volume (30 Days)
- GEVO 4.3M
- EBS 1.5M
- Earning Date
- GEVO 11-10-2025
- EBS 10-29-2025
- Dividend Yield
- GEVO N/A
- EBS N/A
- EPS Growth
- GEVO N/A
- EBS N/A
- EPS
- GEVO N/A
- EBS 1.35
- Revenue
- GEVO $120,932,000.00
- EBS $788,900,000.00
- Revenue This Year
- GEVO $909.99
- EBS N/A
- Revenue Next Year
- GEVO $11.14
- EBS $15.42
- P/E Ratio
- GEVO N/A
- EBS $7.48
- Revenue Growth
- GEVO 675.75
- EBS N/A
- 52 Week Low
- GEVO $0.92
- EBS $4.02
- 52 Week High
- GEVO $2.98
- EBS $13.41
- Technical
- Relative Strength Index (RSI)
- GEVO 36.43
- EBS 50.08
- Support Level
- GEVO $1.83
- EBS $9.93
- Resistance Level
- GEVO $2.27
- EBS $11.02
- Average True Range (ATR)
- GEVO 0.14
- EBS 0.83
- MACD
- GEVO -0.05
- EBS -0.11
- Stochastic Oscillator
- GEVO 13.89
- EBS 21.43
About GEVO Gevo Inc.
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.